and after balloon angioplasty in 40 consecutive patients with iliac artery stenoses. ...... arteries after percutaneous transluminal coronary angioplasty. Am.
ple, repetitive exercises to create muscular exertion. ... The exercises are designed to increase muscle .... vical verte bra, the stabilization of the scapula, the.
INCOME INEQUALITY: DOES IT MATTER?
How Much Does Evaluation Matter?
Operations Evaluation Department of the World Bank, USA. This article .... Journalists were given basic training in ... This training was delivered through (1) mini press conferences; (2) simulation exercises ..... A Follow-up on the Tracer Study.
Jan 1, 2011 - This Article is brought to you for free and open access by the Animal Science ... (Definition sources are primarily from Wikipedia, the free on-line encyclopedia at ... and control its functions. Cattle have 30 chromosome pairs. Allele.
Dec 24, 2004 - QGP (RBRC Scientific Articles, Vol. 9, Brookhaven National Laboratory, Upton, NY, USA), to appear as a special volume in Nucl. Phys. A.
Dec 1, 2007 - The entire grazing season lasted 180 days ... paddock every day (24-h) and (2) moving the cattle to a new paddock every three days (72-h). Since there were four grazing circuits across the pasture each year and the.
An Analytical and Empirical Analysis of Heterogeneity of IT Service. Dimensions and the .... (1988) further consolidated these ten dimensions to five. Yang and.
Division of Surgical Oncology, University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan.
patient populations most likely to benefit and the development of other adjuvant therapies (such as vaccines) for the rest. Even if this preliminary observation about HLA-A2 status ultimately is proven incorrect, it should serve as a highly visible reminder of the potential value of a better understanding of how (and for whom) interferon works. For clinicians—and clinical trialists—that indeed does matter.
the multicenter Eastern Cooperative Oncology Group Phase II trial E2696. J Clin Oncol. 2001;19:1430 –1436. Pfeffer LM, Dinarello CA, Herberman RB, et al. Biological properties of recombinant alpha-interferons: 40th anniversary of the discovery of interferons. Cancer Res. 1998;58: 2489 –2499. Meyskens FL, Kopecky K, Taylor CW, et al. Randomized trial of adjuvant human interferon gamma versus observation in high-risk cutaneous melanoma. J Natl Cancer Inst. 1995;87: 1710 –1713. Kleeborg U, Broecker EB, Chartier C, et al. EORTC 18871 adjuvant trial in high risk melanoma patients: IFN␣ vs IFN␥ vs Iscador vs observation [abstract]. Eur J Cancer. 1999; 35(Suppl 4):264. Jaffe HS, Herberman RB. Rationale for recombinant human interferon-gamma adjuvant immunotherapy for cancer. J Natl Cancer Inst. 1988;80:616 – 618. Maluish AE, Urba WJ, Longo DL, et al. The determination of an immunologically active dose of interferon-gamma in patients with melanoma. J Clin Oncol. 1988;6:434 – 445. Kirkwood JM, Richards T, Zarour HM, et al. Immunomodulatory effects of high-and low-dose IFNa2b in patients with high-risk resected melanoma: the E2690 laboratory corollary of Intergroup adjuvant trial E1690. Cancer. 2002;95:1101– 1112. Cascinelli N, Bufalino R, Morabito A, et al. Results of adjuvant interferon study in WHO melanoma programme. Lancet. 1994;343:913–914. Fidler IJ. Angiogenesis and cancer metastasis. Cancer J Sci Am. 2000;6(Suppl 2):S134 –S141. McMasters KM. The Sunbelt Melanoma Trial. Ann Surg Oncol. 2001;8(Suppl 9):41– 43. Cameron DA, Cornbleet MC, Mackie RM, et al. Adjuvant interferon alpha 2b in high risk melanoma—the Scottish study. Br J Cancer. 2001;84:1146 –1149. Hancock BW, Wheatley K, Harrison G, Gore M. Aim highadjuvant interferon in melanoma (high risk), a United Kingdom Co-ordinating Committee on Cancer Research (UKCCCR) randomised study of observation versus adjuvant low dose extended duration interferon alpha-2a in high risk resected malignant melanoma [abstract]. Proc Am Soc Clin Oncol. 2001;20:349a. Eggermont AMM, Kleeberg U, Ruiter DJ. European Organization for Research and Treatment of Cancer Melanoma Group trial experience with more than 2,000 patients, evaluating adjuvant treatment with low or intermediate doses of interferon alpha-2b. In: Perry MC, editor. American Society of Clinical Oncology 2001 educational book. Baltimore: Lippincott, Williams, Wilkins, 2001:88 –93.